Celldex Therapeutics Inc. (NASDAQ:CLDX) and CRISPR Therapeutics AG (NASDAQ:CRSP) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics Inc.	11.23M	6.26	145.62M	-1.16	0.00
CRISPR Therapeutics AG	35.33M	58.13	117.25M	-2.35	0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Celldex Therapeutics Inc. and CRISPR Therapeutics AG.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics Inc.	-1,296.71%	-93%	-68.2%
CRISPR Therapeutics AG	-331.87%	-40.4%	-30.9%

Liquidity

The current Quick Ratio of Celldex Therapeutics Inc. is 6.6 while its Current Ratio is 6.6. Meanwhile, CRISPR Therapeutics AG has a Current Ratio of 15.4 while its Quick Ratio is 15.4. CRISPR Therapeutics AG is better positioned to pay off its short-term and long-term debts than Celldex Therapeutics Inc.

Insider and Institutional Ownership

The shares of both Celldex Therapeutics Inc. and CRISPR Therapeutics AG are owned by institutional investors at 29.4% and 47.7% respectively. Celldex Therapeutics Inc.’s share held by insiders are 0.2%. Insiders Comparatively, held 0.5% of CRISPR Therapeutics AG shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Celldex Therapeutics Inc.	-7.6%	-18.11%	-35.84%	-58.49%	-90.58%	-90.29%
CRISPR Therapeutics AG	-7.91%	-9.14%	-28.96%	-40.74%	84.43%	50.34%

For the past year Celldex Therapeutics Inc. had bearish trend while CRISPR Therapeutics AG had bullish trend.

Summary

CRISPR Therapeutics AG beats on 9 of the 10 factors Celldex Therapeutics Inc.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.